STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer." The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expirati ...

The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world, including a pending patent application in Europe. Calliditas read out positive topline results of its Phase 2 head and neck cancer trial with setanaxib in May 2024. The analysis showed ...

Allocation of profit or loss The annual general meeting further resolved, in accordance with the nomination committee's proposal and for the time period until the end of the next annual general meeting, that the directors' fees shall be paid with SEK 940,000 to the chairman of the Board of Directors and SEK 365,000 to each one of the other members who are not employed in the group, SEK 200,000 to the chairman of the audit committee and SEK 100,000 to the other members of the audit committee who are not empl ...

Before you hire a law firm, you should talk to a lawyer and ask: NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the ...

NEW YORK, June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding share ...

STOCKHOLM, May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). Kinpeygo, which was granted conditional marketing authorisation in EU on 15 July 2022, was the ...

STOCKHOLM, May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). Kinpeygo, which was granted conditional marketing authorisation in EU on 15 July 2022, was the ...

STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024. The presented efficacy analysis of Nefecon and sparsentan showed that t ...

Core Viewpoint - The Board of Directors of Calliditas Therapeutics AB unanimously recommends that shareholders accept the public tender offer from Asahi Kasei Corporation, which values the company at SEK 11,164 million [1][3][18]. Group 1: Offer Details - Asahi Kasei has proposed a cash offer of SEK 208 per share and SEK 416 per American Depositary Share (ADS), representing a total offer value of SEK 11,164 million [3][14]. - The offer includes a premium of approximately 83% compared to the closing price of SEK 113.6 on May 27, 2024, and a premium of 74% compared to the closing price of USD 22.42 for the ADS on May 24, 2024 [9][14]. - The acceptance period for the offer is expected to start around July 18, 2024, and end around August 30, 2024, subject to extensions [4]. Group 2: Board's Evaluation - The Board has evaluated the offer based on the company's current market position, future opportunities, and associated risks, considering valuation methods typically used for public offers [11][17]. - The Board believes that the combination with Asahi Kasei will enhance Calliditas' product offerings and accelerate revenue growth and pipeline development [12][18]. - The Board has also noted the Irrevocable Undertakings from the three largest securityholders, representing approximately 44.65% of the total shares, to accept the offer [15]. Group 3: Financial Advisory - Lazard AB is acting as the financial advisor to Calliditas and has provided an opinion that the offer consideration is fair from a financial perspective [8][10][31]. - The financial advisory fee is contingent on the size of the offer consideration and whether the offer is completed [31]. Group 4: Strategic Implications - The proposed acquisition aims to address unmet medical needs in IgA nephropathy, focusing on the continued development of Calliditas' first-to-market product in this area [13]. - Asahi Kasei has expressed its commitment to retaining Calliditas' management and employees while potentially integrating operations for efficiency [18].

STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares ("ADS") of Calliditas Therapeutics AB (publ) (jointly the "Securityholders") accept the public tender offer by Asahi Kasei Corporation. Background This statement is made by the Board of Directors (the "Board") of Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") pursuant to section II.19 of the Nasdaq Stockh ...